{"nctId":"NCT01874145","briefTitle":"Safety and Tolerability of Glatiramer Acetate","startDateStruct":{"date":"2013-06"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"count":209,"armGroups":[{"label":"GA 20 mg/mL every day","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: GA 20 mg/mL"]},{"label":"GA 40 mg/mL 3 times a week","type":"EXPERIMENTAL","interventionNames":["Drug: GA 40 mg/mL"]}],"interventions":[{"name":"GA 20 mg/mL","otherNames":["Glatiramer Acetate","Copaxone®"]},{"name":"GA 40 mg/mL","otherNames":["Glatiramer Acetate","Copaxone®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men or women at least 18 years of age or older\n2. Subjects must have a confirmed and documented RRMS diagnosis as defined by the Revised McDonald criteria, with relapse onset disease or a relapsing-remitting disease course\n3. Subjects must be ambulatory with a Kurtzke Expanded Disability Status Scale (EDSS) score of 0-5.5 in both the Screening and Baseline visits.\n4. Subjects must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment \\[intravenous (IV), intramuscular (IM) and/or per os (PO)\\] or adrenocorticotrophic hormone (ACTH), 60 days prior to randomization.\n5. Subjects must be treated with Glatiramer Acetate (GA) 20mg/mL QD SC injection for a minimum of 6 months prior to screening.\n6. Women of child-bearing potential must practice an acceptable method of birth control \\[acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or a double-barrier method (condom or diaphragm with spermicide)\\].\n7. Subjects must be able to sign and date a written informed consent prior to entering the study.\n8. Subjects must be willing and able to comply with the protocol requirements for the duration of the study\n\nExclusion Criteria:\n\n1. Subject has any contraindication to Glatiramer Acetate therapy\n2. Subjects with progressive forms of multiple sclerosis (MS).\n3. Subjects with Neuromyelitis Optica (NMO).\n4. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.\n5. Concomitant use of other disease modifying drug for MS ((Fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), Teriflunomide (Aubagio®) or intravenous immunoglobulin (IVIG)) within 6 months prior to screening\n6. Previous use of mitoxantrone, cladribine, alemtuzumab, rituximab, natalizumab.\n7. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.\n8. Previous total body irradiation or total lymphoid irradiation.\n9. Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.\n10. Pregnancy or breastfeeding.\n11. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG and abnormal laboratory tests. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.\n12. Subjects who underwent endovascular treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI).\n13. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals -","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Estimates for Injection-Related Adverse Event Rate Per Year in the Core Period","description":"Injection-related (IR) adverse events refers to all local injection site reactions and/or symptoms or events related to immediate post injection reaction (flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and/or urticaria). Rate was calculated as # IR events/the total exposure to study drug in years.\n\nFor cases in which more than 1 IR adverse event started on the same date for the same patient, these were counted as 1 IR adverse event for that patient.\n\nParameter statistics were generated from a Poisson regression model with natural log of treatment duration (years) as an offset variable, and adjusted for baseline EDSS score, treatment group, age, sex, number of relapses in the 2 years prior to screening, in which a contrast comparing treatment groups were constructed. Adjusted mean estimates were adjusted estimates of event rates within treatment group.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.403","spread":"11.995"},{"groupId":"OG001","value":"35.275","spread":"7.248"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Adverse Events Other Than Injection Related Reactions During the Core Period and the Extension Period","description":"An adverse event was defined in the protocol as any untoward medical occurrence in a patient that developed or worsened in severity during the conduct of the clinical study of a pharmaceutical product and did not necessarily have a causal relationship to the study drug. This outcome summarizes the % of participants who had AEs other than injection related reactions. Injection-related (IR) adverse events referring to all local injection site reactions and/or symptoms or events related to immediate post injection reaction (flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and/or urticaria).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":null},{"groupId":"OG001","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"39.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Estimates for Injection Site Reaction Event Rate Per Year in the Core Period","description":"This outcome includes injection-related adverse events referring to all local injection site reactions (ISR). Rate was calculated as # ISR events/the total exposure to study drug in years.\n\nFor cases in which more than 1 ISR adverse event started on the same date for the same patient, these were counted as 1 ISR adverse event for that patient.\n\nParameter statistics were generated from a Poisson regression model with natural log of treatment duration (years) as an offset variable, and adjusted for baseline EDSS score, treatment group, age, sex, number of relapses in the 2 years prior to screening, in which a contrast comparing treatment groups were constructed. Adjusted mean estimates were adjusted estimates of event rates within treatment group.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.392","spread":"12.007"},{"groupId":"OG001","value":"35.200","spread":"7.247"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Impact on Physical Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO) in the Core Period","description":"The physical wellbeing assessment portion of the MSIS-29 is comprised of 20 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 20-100. Negative change from baseline scores indicate improvement in physical wellbeing over time.\n\nThe estimated change from baseline to month 4 adjusted for months 1 and 2 was generated using a mixed model repeated measures analysis adjusted for baseline MSIS-29 physical score, treatment group, month, treatment by month interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.536","spread":"0.868"},{"groupId":"OG001","value":"-0.522","spread":"0.832"}]}]}]},{"type":"PRIMARY","title":"Injection-Related Adverse Event Rate Per Year in the Extension Period","description":"Injection-related (IR) adverse events refers to all local injection site reactions and/or symptoms or events related to immediate post injection reaction (flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and/or urticaria). Rate was calculated as # IR events/the total exposure to study drug in years.\n\nFor cases in which more than 1 IR adverse event started on the same date for the same patient, these were counted as 1 IR adverse event for that patient.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"28.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Impact on Psychological Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO) in the Core Period","description":"The psychological wellbeing assessment portion of the MSIS-29 is comprised of 9 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 9-45. Negative change from baseline scores indicate improvement in psychological wellbeing over time.\n\nThe estimated change from baseline to month 4 adjusted for months 1 and 2 was generated using a mixed model repeated measures analysis adjusted for baseline MSIS-29 psychological score, treatment group, month, treatment by month interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.738","spread":"0.533"},{"groupId":"OG001","value":"0.016","spread":"0.512"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Convenience Score in the Core Period","description":"The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. This outcome focuses on convenience items 4-6, with each question graded on a scale of 1 (extreme dissatisfaction) to 7 (extreme satisfaction). TSQM-9 participant perception of convenience score was calculated as: (\\[sum (Item 4 to Item 6) - 3\\] divided by 18) \\* 100. The full range was -100 to 100, with positive change from baseline indicating improvement.\n\nThe estimated change from baseline to month 4 adjusted for months 1 and 2 was generated using a mixed model repeated measures analysis adjusted for baseline TSQM convenience score, treatment group, month, treatment by month interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.745","spread":"1.457"},{"groupId":"OG001","value":"8.751","spread":"1.399"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Satisfaction Score in the Core Period","description":"The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. This outcome focuses on global satisfaction, items 7-9. TSQM-9 participant perception of satisfaction score was calculated as: (\\[sum(Item 7 to Item 9) - 3\\] divided by 14) \\* 100. The full range was -100 to 100, with positive change from baseline indicating improvement satisfaction with medication.\n\nThe estimated change from baseline to month 4 adjusted for months 1 and 2 was generated using a mixed model repeated measures analysis adjusted for baseline TSQM convenience score, treatment group, month, treatment by month interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.555","spread":"1.489"},{"groupId":"OG001","value":"0.703","spread":"1.431"}]}]}]},{"type":"SECONDARY","title":"Injection Site Reaction Event Rate Per Year in the Extension Period","description":"This outcome includes injection-related adverse events referring to all local injection site reactions (ISR). Rate was calculated as # ISR events/the total exposure to study drug in years.\n\nFor cases in which more than 1 ISR adverse event started on the same date for the same patient, these were counted as 1 ISR adverse event for that patient.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"28.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Injection Site Reaction Events in the Extension Period","description":"This outcome includes injection-related adverse events referring to all local injection site reactions (ISR).\n\nFor cases in which more than 1 ISR adverse event started on the same date for the same patient, these were counted as 1 ISR adverse event for that patient.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"768","spread":null},{"groupId":"OG001","value":"976","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Start of Extension Period (Month 4) to Month 8 (and to Endpoint Visit) in the Participant-Reported Impact on Physical Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO)","description":"The physical wellbeing assessment portion of the MSIS-29 is comprised of 20 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 20-100. Negative change from baseline scores indicate improvement in physical wellbeing.\n\nThe Extension Period endpoint visit was defined as the last observed post-baseline data of the Extension Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"8.09"},{"groupId":"OG001","value":"0.8","spread":"9.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"7.53"},{"groupId":"OG001","value":"0.6","spread":"7.60"}]}]}]},{"type":"SECONDARY","title":"Change From Start of Extension Period (Month 4) to Month 8 (and to Endpoint Visit) in the Participant-Reported Impact on Psychological Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO)","description":"The psychological wellbeing assessment portion of the MSIS-29 is comprised of 9 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 9-45. Negative change from baseline scores indicate improvement in psychological wellbeing.\n\nThe Extension Period endpoint visit was defined as the last observed post-baseline data of the Extension Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"4.34"},{"groupId":"OG001","value":"0.4","spread":"5.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"5.26"},{"groupId":"OG001","value":"0.2","spread":"3.83"}]}]}]},{"type":"SECONDARY","title":"Change From Start of Extension Period to Month 8 (and to Endpoint Visit) in in the Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Convenience Score","description":"The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. This outcome focuses on convenience items 4-6, with each question graded on a scale of 1 (extreme dissatisfaction) to 7 (extreme satisfaction). TSQM-9 participant perception of convenience score was calculated as: (\\[sum (Item 4 to Item 6) - 3\\] divided by 18) \\* 100. The full range was -100 to 100, with positive change from baseline indicating improvement.\n\nThe Extension Period endpoint visit was defined as the last observed post-baseline data of the Extension Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"18.44"},{"groupId":"OG001","value":"-0.2","spread":"10.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"17.41"},{"groupId":"OG001","value":"-0.2","spread":"13.10"}]}]}]},{"type":"PRIMARY","title":"Injection-Related Adverse Events in the Extension Period","description":"Injection-related (IR) adverse events refers to all local injection site reactions and/or symptoms or events related to immediate post injection reaction (flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and/or urticaria).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"772","spread":null},{"groupId":"OG001","value":"979","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Start of Extension Period to Month 8 (and to Endpoint Visit) in in the Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Satisfaction Score","description":"The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. This outcome focuses on global satisfaction, items 7-9. TSQM-9 participant perception of satisfaction score was calculated as: (\\[sum(Item 7 to Item 9) - 3\\] divided by 14) \\* 100. The full range was -100 to 100, with positive change from baseline indicating improvement satisfaction with medication.\n\nThe Extension Period endpoint visit was defined as the last observed post-baseline data of the Extension Period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"14.50"},{"groupId":"OG001","value":"-1.2","spread":"13.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"14.32"},{"groupId":"OG001","value":"-1.2","spread":"11.11"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["Injection site pain","Injection site erythema","Injection site mass","Injection site swelling","Injection site pruritus"]}}}